Sentences with phrase «therapy than current treatments»

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

«As these drugs are considerably cheaper than current therapies, they can improve treatment in the developing world where the number of deaths from cancer is predicted to increase significantly over the next ten years,» said Dr Federica Sotgia, another leader of the study.

Neither is from Burdick's lab, but as he notes, «It's important we all keep moving forward to figure out how this therapy could be used, because it's different than any current treatment.»

«Despite having good treatments available, current reports suggest that fewer than half of individuals who need therapy are actually getting appropriate HIV medicine to control their virus, leading to more transmission of disease,» says lead study author Maunank Shah, M.D., Ph.D., an assistant professor of medicine at the Johns Hopkins University School of Medicine.

Placing a high value on therapies that are expensive to develop and deliver, but ultimately cost less over the long - term than current treatment.

Those early results are very positive, and strongly indicate that the nanoparticles could be useful for assessing how effective a therapy is on a much shorter time scale than current treatments, which usually rely on observing the size of the tumor.

«Treatment with the medication as performed in the study results in more vision improvement and less vision loss than current laser therapy alone, and it doesn't increase eye pressure or cataracts.»

«Treatment with the anti-VEGF medication as performed in the study results in more vision improvement and less vision loss than current laser therapy alone, and it doesn't increase eye pressure or cataracts.»

Although clinical trials offer no guarantees, physicians have a strong belief that the study drug or cancer treatment will provide benefits equal to or better than the current standard therapies.

Current thermal ablation, or heat therapy, treatments for human tumors include radiofrequency ablation, which applies a single - point source of heat to the tumor rather than evenly heating the tumor throughout, like the MWCNTs were able to.

No therapies for IBS are perfect, but nearly every other current treatment studied works better than Rifaximin.13, 14

The care co-ordination aspect of the intervention was based on current National Institute for Health and Care Excellence (NICE) guidance.17 18 BA is a simple psychological treatment for depression that aims to re-engage patients with positively reinforcing experiences and reduce avoidance behaviours.19 It is no less clinically effective but more cost effective than cognitive behavioural therapy in treating depression in adults.20